In the BioHarmony Drug Report Database

"Preview" Icon

Rilpivirine

Edurant, Rekambys (rilpivirine) is a small molecule pharmaceutical. Rilpivirine was first approved as Edurant on 2011-05-20. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. Edurant’s patents are valid until 2025-04-21 (FDA).

 

Trade Name

 

Edurant, Rekambys
 

Common Name

 

rilpivirine
 

ChEMBL ID

 

CHEMBL175691
 

Indication

 

hiv infections
 

Drug Class

 

Antivirals: non-nucleoside reverse transcriptase inhibitors, not benzoxazinone derivatives

Image (chem structure or protein)

Rilpivirine structure rendering